142 related articles for article (PubMed ID: 21539821)
21. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies.
Horbinski C; Kelly L; Nikiforov YE; Durso MB; Nikiforova MN
J Mol Diagn; 2010 Jul; 12(4):487-92. PubMed ID: 20431032
[TBL] [Abstract][Full Text] [Related]
22. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
[TBL] [Abstract][Full Text] [Related]
23. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.
Preusser M; Wöhrer A; Stary S; Höftberger R; Streubel B; Hainfellner JA
J Neuropathol Exp Neurol; 2011 Aug; 70(8):715-23. PubMed ID: 21760534
[TBL] [Abstract][Full Text] [Related]
24. Detection of IDH1 R132H mutation in acute myeloid leukemia by mutation-specific immunohistochemistry.
Byers R; Hornick JL; Tholouli E; Kutok J; Rodig SJ
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):37-40. PubMed ID: 22172803
[TBL] [Abstract][Full Text] [Related]
25. Validation of high-resolution DNA melting analysis for mutation scanning of the CDKL5 gene: identification of novel mutations.
Raymond L; Diebold B; Leroux C; Maurey H; Drouin-Garraud V; Delahaye A; Dulac O; Metreau J; Melikishvili G; Toutain A; Rivier F; Bahi-Buisson N; Bienvenu T
Gene; 2013 Jan; 512(1):70-5. PubMed ID: 23064044
[TBL] [Abstract][Full Text] [Related]
26. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Takano S; Tian W; Matsuda M; Yamamoto T; Ishikawa E; Kaneko MK; Yamazaki K; Kato Y; Matsumura A
Brain Tumor Pathol; 2011 Apr; 28(2):115-23. PubMed ID: 21344322
[TBL] [Abstract][Full Text] [Related]
27. Detection of IDH1 mutation in the plasma of patients with glioma.
Boisselier B; Gállego Pérez-Larraya J; Rossetto M; Labussière M; Ciccarino P; Marie Y; Delattre JY; Sanson M
Neurology; 2012 Oct; 79(16):1693-8. PubMed ID: 23035067
[TBL] [Abstract][Full Text] [Related]
28. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
[TBL] [Abstract][Full Text] [Related]
29. Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
Ibáñez M; Such E; Cervera J; Luna I; Gómez-Seguí I; López-Pavía M; Dolz S; Barragán E; Fuster O; Llop M; Rodríguez-Veiga R; Avaria A; Oltra S; Senent ML; Moscardó F; Montesinos P; Martínez-Cuadrón D; Martín G; Sanz MA
J Mol Diagn; 2012 Nov; 14(6):594-601. PubMed ID: 22929312
[TBL] [Abstract][Full Text] [Related]
30. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.
Ho PA; Alonzo TA; Kopecky KJ; Miller KL; Kuhn J; Zeng R; Gerbing RB; Raimondi SC; Hirsch BA; Oehler V; Hurwitz CA; Franklin JL; Gamis AS; Petersdorf SH; Anderson JE; Reaman GH; Baker LH; Willman CL; Bernstein ID; Radich JP; Appelbaum FR; Stirewalt DL; Meshinchi S
Leukemia; 2010 May; 24(5):909-13. PubMed ID: 20376086
[TBL] [Abstract][Full Text] [Related]
31. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
32. IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.
Lu J; Xu L; Zou Y; Yang RX; Fan Y; Zhang W; Yu D; Yao YG
Med Sci Monit; 2014 Feb; 20():247-54. PubMed ID: 24531386
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.
Zhu YM; Foroni L; McQuaker IG; Papaioannou M; Haynes A; Russell HH
Br J Cancer; 1999 Mar; 79(7-8):1151-7. PubMed ID: 10098750
[TBL] [Abstract][Full Text] [Related]
34. Rapid identification of IDH1 and IDH2 mutations in acute myeloid leukaemia using high resolution melting curve analysis.
Noordermeer SM; Tönnissen E; Vissers I; van der Heijden A; van de Locht LT; Deutz-Terlouw PP; Marijt EW; Jansen JH; van der Reijden BA
Br J Haematol; 2011 Feb; 152(4):493-6. PubMed ID: 20955413
[No Abstract] [Full Text] [Related]
35. A comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning: cystic fibrosis transmembrane conductance regulator gene as a model.
Chou LS; Lyon E; Wittwer CT
Am J Clin Pathol; 2005 Sep; 124(3):330-8. PubMed ID: 16191501
[TBL] [Abstract][Full Text] [Related]
36. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
Benthaus T; Schneider F; Mellert G; Zellmeier E; Schneider S; Kakadia PM; Hiddemann W; Bohlander SK; Feuring-Buske M; Braess J; Spiekermann K; Dufour A
Br J Haematol; 2008 Oct; 143(2):230-9. PubMed ID: 18752591
[TBL] [Abstract][Full Text] [Related]
37. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
Andrulis M; Capper D; Luft T; Hartmann C; Zentgraf H; von Deimling A
Leuk Res; 2010 Aug; 34(8):1091-3. PubMed ID: 20227112
[TBL] [Abstract][Full Text] [Related]
38. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
39. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
Sritana N; Auewarakul CU
Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
[TBL] [Abstract][Full Text] [Related]
40. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
